• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Advanced Inhalation Therapies raises $10m

February 2, 2017 By Sarah Faulkner

Advanced Inhalation Therapies raises $10mAdvanced Inhalation Therapies closed a $10.2 million offering yesterday. According to regulatory filings, 39 investors contributed to the offering, which made its 1st sale on Jan. 13.

The Israel-based company is developing a drug delivery device to treat severe respiratory infections and lung diseases using a high dose of nitric oxide.

The company plans to use $604,000 from the offering to compensate Ladenburg Thalmann & Co. Inc. for sales and $150,000 for executive officers, directors or promoters.

AIT has not made a formal statement about the offering.

The company is developing NOxSysBS, a system designed to deliver a gaseous, high-dose blend of nitric oxide, oxygen and air. The FDA has approved a 20 ppm nitric oxide vasodilation treatment, which AIT claims is not effective for treating microbial infections.

AIT’s NOxSysBS device delivers 160 ppm of nitric oxide, according to the company. The human body naturally produces nitric oxide on its own to fight infections.

The company, founded in 2011, pinpointed its initial targets as a pair of lower respiratory tract infections, children with bronchitis and lung infections in patients with cystic fibrosis.

In January last year, AIT scaled back its pending initial public offering by more than 2/3.

When it registered for the IPO in August 2015, AIT sent the high end of the offering at $36 million. Last year, the company said it plans to float 675,000 shares at $15 apiece, yielding gross proceeds of $10.1 million.

AIT plans to list on the NASDAQ exchange under the “AITP” symbol.

Filed Under: Featured, Funding Roundup, Respiratory, Wall Street Beat Tagged With: Advanced Inhalation Therapies

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS